Evidence map›Paper›PMID 39742357›Full record

ArticleThe breast journal2024

Unveiling miRNA30b's Role in Suppressing ADAM12 to Combat Triple-Negative Breast Cancer.

Qing-Hua Yin, Jian-Bing Hu, Qiang Zhou, Jie Weng, Er-Dong Shen, Fang Wen, Song-Lian Liu, Lei-Lan Yin, Ya-Jun Tong, Ling Long and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The breast journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Qing-Hua YinDepartment of Oncology, Yueyang Central Hospital, Yueyang 414000, Hunan, China.ORCID 0009-0007-6721-5937
Jian-Bing HuDepartment of Oncology, Yueyang Central Hospital, Yueyang 414000, Hunan, China.ORCID 0009-0001-2602-716X
Qiang ZhouDepartment of Oncology, Yueyang Central Hospital, Yueyang 414000, Hunan, China.
Jie WengDepartment of Oncology, Yueyang Central Hospital, Yueyang 414000, Hunan, China.
Er-Dong ShenDepartment of Oncology, Yueyang Central Hospital, Yueyang 414000, Hunan, China.
Fang WenDepartment of Oncology, Yueyang Central Hospital, Yueyang 414000, Hunan, China.
Song-Lian LiuDepartment of Oncology, Yueyang Central Hospital, Yueyang 414000, Hunan, China.
Lei-Lan YinDepartment of Oncology, Yueyang Central Hospital, Yueyang 414000, Hunan, China.
Ya-Jun TongDepartment of Oncology, Yueyang Central Hospital, Yueyang 414000, Hunan, China.
Ling LongDepartment of Oncology, Yueyang Central Hospital, Yueyang 414000, Hunan, China.
Ke-Wei TangDepartment of Oncology, Yueyang Central Hospital, Yueyang 414000, Hunan, China.
Si-Te BaiDepartment of Oncology, Yueyang Central Hospital, Yueyang 414000, Hunan, China.
Lu-di OuDepartment of Oncology, Yueyang Central Hospital, Yueyang 414000, Hunan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

ADAM12 ProteinCell MovementCell ProliferationMicroRNAsTriple Negative Breast NeoplasmsCell Line, TumorDown-RegulationFemaleGene Expression Regulation, NeoplasticHumansNeoplasm InvasivenessADAM12 ProteinADAM12 protein, humanMicroRNAsADAM12invasionmigrationmiRNA30bproliferationtriple-negative breast cancer

Identifiers

PMID39742357
PMCPMC11540880

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.